Santos J E, Bremner C G, Allen C, Warman B, Fotheringham G, Chleboun J O
S Afr Med J. 1984 Jun 23;65(25):1005-6.
Fifty patients with acute upper gastro-intestinal haemorrhage were given either oral or intravenous ranitidine ( Zantac ; Glaxo), the route of administration being allocated on a random basis. Two patients were excluded from the oral group and 5 were excluded from the intravenous group. The two groups were similar as regards age, sex, number of patients aged over 60 years and severity of bleeding. All the patients were carefully monitored for rebleeding, which occurred in a total of 7 cases (16,3%), 6 in the oral group (26%) and 1 in the intravenous group (5%). Statistically this represented a marked tendency towards a significantly lower incidence of recurrent haemorrhage in the patients treated with intravenous ranitidine (P = 0,07, tested according to Fisher's exact method). No patient in the intravenous group who bled again came to surgery, while 3 of the 23 patients in the oral group (13%) required surgery.
五十名急性上消化道出血患者被随机分配接受口服或静脉注射雷尼替丁（善胃得；葛兰素公司生产）治疗。口服组有两名患者被排除，静脉注射组有五名患者被排除。两组在年龄、性别、60岁以上患者数量和出血严重程度方面相似。所有患者均被密切监测再出血情况，共有7例（16.3%）发生再出血，口服组6例（26%），静脉注射组1例（5%）。从统计学角度来看，这表明接受静脉注射雷尼替丁治疗的患者复发出血发生率明显较低，具有显著趋势（根据费舍尔精确检验法，P = 0.07）。静脉注射组中再次出血的患者均未接受手术治疗，而口服组的23名患者中有3例（13%）需要手术治疗。
